{"protocolSection": {"identificationModule": {"nctId": "NCT00446563", "orgStudyIdInfo": {"id": "CVAA489ADE02"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy", "officialTitle": "An Open-label, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Amlodipine in Combination With Valsartan Compared to Losartan in Combination With Hydrochlorothiazide Given for 52 Weeks on the Regression of Left Ventricular Hypertrophy in Patients With Mild to Moderate Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-03"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-03-12", "studyFirstSubmitQcDate": "2007-03-12", "studyFirstPostDateStruct": {"date": "2007-03-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-03-31", "resultsFirstSubmitQcDate": "2011-03-31", "resultsFirstPostDateStruct": {"date": "2011-04-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-05-06", "lastUpdatePostDateStruct": {"date": "2011-05-11", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study will evaluate the safety and efficacy of amlodipine plus valsartan in patients with hypertension and left ventricular hypertrophy"}, "conditionsModule": {"conditions": ["Hypertension; Hypertrophy, Left Ventricular"], "keywords": ["Left ventricular hypertrophy, hypertension, valsartan, amlodipine"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 90, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Amlodipine + Valsartan", "type": "EXPERIMENTAL", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.", "interventionNames": ["Drug: Valsartan", "Drug: Amlodipine"]}, {"label": "Losartan + Hydrochlorothiazide", "type": "ACTIVE_COMPARATOR", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.", "interventionNames": ["Drug: Hydrochlorothiazide", "Drug: Losartan"]}], "interventions": [{"type": "DRUG", "name": "Valsartan", "description": "160 mg film coated tablets taken orally once daily in the morning.", "armGroupLabels": ["Amlodipine + Valsartan"]}, {"type": "DRUG", "name": "Amlodipine", "description": "5 mg or 10 mg tablets taken orally once daily in the morning.", "armGroupLabels": ["Amlodipine + Valsartan"]}, {"type": "DRUG", "name": "Hydrochlorothiazide", "description": "12.5 mg or 25 mg tablets taken orally once daily in the morning.", "armGroupLabels": ["Losartan + Hydrochlorothiazide"]}, {"type": "DRUG", "name": "Losartan", "description": "100 mg tablets taken orally once daily in the morning.", "armGroupLabels": ["Losartan + Hydrochlorothiazide"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)", "timeFrame": "Baseline to week 52"}], "secondaryOutcomes": [{"measure": "Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI", "description": "Ejection fraction is a measurement of the percentage of blood that is pumped out of a filled ventricle with each heartbeat.", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)", "timeFrame": "Baseline to week 52"}, {"measure": "Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)", "timeFrame": "Baseline to week 52"}, {"measure": "Percentage of Participants Achieving Target Blood Pressure at Week 52", "description": "Target blood pressure defined as having a mean sitting systolic blood pressure (MSSBP) \\< 140 mm Hg and a mean sitting diastolic blood pressure (MSDBP) \\< 90 mm Hg.", "timeFrame": "Week 52"}, {"measure": "Percentage of Participants Who Experienced Adverse Events (AEs)", "description": "An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after obtaining informed consent even if the event was not considered to be related to study drug. Medical conditions/diseases present before obtaining informed consent were only considered adverse events if they worsened after study start. Abnormal laboratory values or test results constituted adverse events only if they induced clinical signs or symptoms, required study drug discontinuation or required therapy.", "timeFrame": "Baseline to week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Caucasian; male or female outpatients and age between 18-80 years of age, inclusive.\n* Patients with a history of essential hypertension and who are actually treated either with an antihypertensive monotherapy and with a diastolic blood pressure \\>=90 and \\<= 105mmHg or with a combination therapy (limited to two active compounds) and with a diastolic blood pressure of \\>=90 and \\<= 100mmHg.\n* Patients with Left Ventricular Hypertrophy\n\nExclusion Criteria:\n\n* Severe hypertension\n* Symptomatic heart failure\n* History of stroke, heart attack, coronary bypass surgery etc.\n* Insulin-dependent diabetes mellitus or poorly controlled diabetes mellitus.\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "80 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_CHAIR"}], "locations": [{"facility": "25 centers in Germany", "city": "Ludwigshafen", "country": "Germany", "geoPoint": {"lat": 49.48121, "lon": 8.44641}}]}, "referencesModule": {"references": [{"pmid": "27536421", "type": "DERIVED", "citation": "Bruder O, Jensen CJ, Bell M, Rummel R, Boehm G, Klebs S, Sieder C, Senges J. Effects of the combinations of amlodipine/valsartan versus losartan/hydrochlorothiazide on left ventricular hypertrophy as determined with magnetic resonance imaging in patients with hypertension. J Drug Assess. 2011 Dec 16;1(1):1-10. doi: 10.3109/21556660.2011.639418. eCollection 2012."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "FG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "43"}, {"groupId": "FG001", "numSubjects": "47"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "38"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "9"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Abnormal laboratory value(s)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Abnormal test procedure result(s)", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "BG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "90"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.2", "spread": "12.2"}, {"groupId": "BG001", "value": "57.2", "spread": "10.9"}, {"groupId": "BG002", "value": "57.7", "spread": "11.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "25"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "65"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Left Ventricular Mass Index (LVMI) Measured Via Magnetic Resonance Imaging (MRI)", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/m\u02c42", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.1", "spread": "16.50"}, {"groupId": "OG001", "value": "-9.1", "spread": "18.89"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Left Ventricular Mass Index (LVMI) Normalized to Body Surface Area Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g/m\u02c42", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.5", "spread": "7.4"}, {"groupId": "OG001", "value": "-4.4", "spread": "9.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Interventricular Septum Thickness (IVS) Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "1.5"}, {"groupId": "OG001", "value": "-0.6", "spread": "1.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Posterior Wall Thickness Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "1.1"}, {"groupId": "OG001", "value": "-0.3", "spread": "1.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Left Ventricular Ejection Fraction (LVEF) Assessed by MRI", "description": "Ejection fraction is a measurement of the percentage of blood that is pumped out of a filled ventricle with each heartbeat.", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "6.7"}, {"groupId": "OG001", "value": "-0.4", "spread": "5.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "19.9"}, {"groupId": "OG001", "value": "-6.4", "spread": "22.9"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Left Ventricular End-diastolic Volume (LVEDV) Normalized to Body Surface Area Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "9.6"}, {"groupId": "OG001", "value": "-3.0", "spread": "11.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "10.3"}, {"groupId": "OG001", "value": "-1.5", "spread": "10.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Left Ventricular End-Systolic Volume (LVESV) Normalized to Body Surface Area Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "5.1"}, {"groupId": "OG001", "value": "-0.8", "spread": "5.1"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in Left Atrial (LA) Area Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "cm\u02c42", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.6", "spread": "3.2"}, {"groupId": "OG001", "value": "-1.0", "spread": "4.5"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to the End of Study in the Ascending Aortic Diameter Assessed by MRI", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "1.9"}, {"groupId": "OG001", "value": "-0.8", "spread": "1.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Study in Levels of N-terminal Pro-B Type Natriuretic Peptide (NT-proBNP)", "populationDescription": "The safety population consisted of the sample of all randomized patients who applied study medication at least once.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.5", "spread": "56.41"}, {"groupId": "OG001", "value": "-40.1", "spread": "74.09"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to End of Study in Levels of High-sensitivity C-reactive Protein (Hs-CRP)", "populationDescription": "The safety population consisted of the sample of all randomized patients who applied study medication at least once.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/l", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.8", "spread": "6.09"}, {"groupId": "OG001", "value": "-2.1", "spread": "9.90"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving Target Blood Pressure at Week 52", "description": "Target blood pressure defined as having a mean sitting systolic blood pressure (MSSBP) \\< 140 mm Hg and a mean sitting diastolic blood pressure (MSDBP) \\< 90 mm Hg.", "populationDescription": "The intention-to-treat (ITT) population consisted of all patients from the safety population who had a baseline MRI assessment. If patients dropped out prior to the scheduled observation period, every effort should have been taken to get a final MRI scan which could then be used for the ITT analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "53.5"}, {"groupId": "OG001", "value": "14.9"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Who Experienced Adverse Events (AEs)", "description": "An adverse event was the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after obtaining informed consent even if the event was not considered to be related to study drug. Medical conditions/diseases present before obtaining informed consent were only considered adverse events if they worsened after study start. Abnormal laboratory values or test results constituted adverse events only if they induced clinical signs or symptoms, required study drug discontinuation or required therapy.", "populationDescription": "The safety population consisted of the sample of all randomized patients who applied study medication at least once.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline to week 52", "groups": [{"id": "OG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}, {"id": "OG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "43"}, {"groupId": "OG001", "value": "47"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "69.8"}, {"groupId": "OG001", "value": "68.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Valsartan and Amlodipine", "description": "Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.", "seriousNumAffected": 2, "seriousNumAtRisk": 43, "otherNumAffected": 15, "otherNumAtRisk": 43}, {"id": "EG001", "title": "Losartan and HCTZ", "description": "Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.", "seriousNumAffected": 6, "seriousNumAtRisk": 47, "otherNumAffected": 16, "otherNumAtRisk": 47}], "seriousEvents": [{"term": "BRADYCARDIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "CORONARY ARTERY DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}]}, {"term": "MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}]}, {"term": "TACHYCARDIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "HYDROCELE", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}]}, {"term": "ABDOMINAL PAIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "ANAL HAEMORRHAGE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "CHOLECYSTITIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}]}, {"term": "ERYSIPELAS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "VESTIBULAR NEURONITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "HYPERTRIGLYCERIDAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "HYPOKALAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "OSTEOARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "COLON CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}, {"term": "METASTATIC NEOPLASM", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}]}, {"term": "THALAMIC INFARCTION", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 47}]}], "otherEvents": [{"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 47}]}, {"term": "NAUSEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 47}]}, {"term": "OEDEMA PERIPHERAL", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}]}, {"term": "BRONCHITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 47}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 47}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 47}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 47}]}, {"term": "ECZEMA", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 43}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 47}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000017379", "term": "Hypertrophy, Left Ventricular"}, {"id": "D000006984", "term": "Hypertrophy"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000020763", "term": "Pathological Conditions, Anatomical"}, {"id": "D000006332", "term": "Cardiomegaly"}, {"id": "D000006331", "term": "Heart Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M10035", "name": "Hypertrophy", "asFound": "Hypertrophy", "relevance": "HIGH"}, {"id": "M19658", "name": "Hypertrophy, Left Ventricular", "asFound": "Hypertrophy, Left Ventricular", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M22519", "name": "Pathological Conditions, Anatomical", "relevance": "LOW"}, {"id": "M9420", "name": "Cardiomegaly", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019808", "term": "Losartan"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M21701", "name": "Losartan", "asFound": "Staff", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}